Glutaminase 2 as a therapeutic target in glioblastoma
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2024-11 · 1879 (6) · 189182
DOI: 10.1016/j.bbcan.2024.189182 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2024-11. Verfasst von Rithvik K Veeramachaneni und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioblastoma, Glutaminase, Glutamine. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Georgetown University School of Medicine.
Abstract (Originalsprache)
Glioblastoma (GBM) is the most common malignant primary adult brain tumor. Despite standard-of-care treatment, which consists of surgical resection, temozolomide (TMZ) treatment, and radiotherapy, the prognosis for GBM patients remains poor with a five-year survival rate of 5 %. With treatment, the median survival time is 14 months, suggesting the dire need for new, more effective therapies. Glutaminolysis, the metabolic pathway by which cells can convert glutamine to ATP, is essential for the survival of GBM cells and represents a putative target for treatment. Glutamine replenishes tricarboxylic acid (TCA) cycle intermediates through glutaminolysis. The first step of glutaminolysis, the deamination of glutamine, can be carried out by either glutaminase 1 (GLS) or glutaminase 2 (GLS2). However, it is becoming increasingly clear that these enzymes have opposing functions in GBM; GLS induces deamination of glutamine, thereby acting in an oncogenic fashion, while GLS2 has non-enzymatic, tumor-suppressive functions that are repressed in GBM. In this review, we explore the important role of glutaminolysis and the opposing roles of GLS and GLS2 in GBM. Further, we provide a detailed discussion of GLS2's newly discovered non-enzymatic functions that can be targeted in GBM. We conclude by considering therapeutic approaches that have emerged from the understanding of GLS and GLS2's opposing roles in GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA. Electronic address: Na853@georgetown.edu.
Förderung
- Georgetown University School of Medicine
Zitieren
APA
Veeramachaneni, R. K., Suter, R. K., Rowland, E., Jermakowicz, A., & Ayad, N. G. (2024). Glutaminase 2 as a therapeutic target in glioblastoma. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1879(6), 189182. https://doi.org/10.1016/j.bbcan.2024.189182
Vancouver
Veeramachaneni RK, Suter RK, Rowland E, Jermakowicz A, Ayad NG. Glutaminase 2 as a therapeutic target in glioblastoma. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2024;1879(6):189182. doi:10.1016/j.bbcan.2024.189182
BibTeX
@article{Veeramachaneni2024,
author = {Veeramachaneni, Rithvik K and Suter, Robert K and Rowland, Emma and Jermakowicz, Anna and Ayad, Nagi G},
title = {Glutaminase 2 as a therapeutic target in glioblastoma},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2024},
volume = {1879},
number = {6},
pages = {189182},
doi = {10.1016/j.bbcan.2024.189182}
}
EUVIMED